Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P12931

UPID:
SRC_HUMAN

ALTERNATIVE NAMES:
Proto-oncogene c-Src; pp60c-src

ALTERNATIVE UPACC:
P12931; E1P5V4; Q76P87; Q86VB9; Q9H5A8

BACKGROUND:
The Proto-oncogene tyrosine-protein kinase Src, with alternative names Proto-oncogene c-Src and pp60c-src, is a non-receptor protein tyrosine kinase. It is essential for various biological activities, including apoptosis, migration, and transformation, by phosphorylating key substrates involved in these processes.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in Thrombocytopenia 6, a hematologic disorder leading to increased bleeding risk, the study of Proto-oncogene tyrosine-protein kinase Src holds significant promise for developing targeted therapies to mitigate this and potentially other related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.